Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746559 · ClinicalTrials.gov registry record · Phase 3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
A Phase 3 study of Chronic Kidney Disease and Cardiac Disease, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 736
- Enrollment target
- 20
- Study locations
NCT05746559 is a Phase 3 study of Chronic Kidney Disease and Cardiac Disease that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 736 participants, below the 3,200-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05746559, a Phase 3 study of Chronic Kidney Disease and Cardiac Disease, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 736 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ravulizumab
Study Locations (20)
California
- Research Site - Orange
- Research Site - San Francisco
- Research Site - San Francisco
- Research Site - Stanford
Massachusetts
- Research Site - Boston
- Research Site - Springfield
Missouri
- Research Site - Kansas City
- Research Site - St Louis
New York
- Research Site - Rochester
- Research Site - Valhalla
Arizona
- Research Site - Tucson
Colorado
- Research Site - Aurora
Florida
- Research Site - Weston
Georgia
- Research Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 736 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2027-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05746559
The ClinicalTrials.gov registry entry for NCT05746559 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 736 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,200-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (77% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05746559 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT05746559 about?
NCT05746559 is a clinical study titled "ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE". The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
What is the current status of trial NCT05746559?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 736 participants. The study started on 2023-04-06. Estimated completion is 2027-02-17.
What conditions does trial NCT05746559 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Cardiac Disease, Cardiopulmonary Bypass, CKD.
What interventions are being tested in trial NCT05746559?
The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT05746559?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05746559 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.